Phase I study of twice-weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients with relapsed and/or refractory multiple myeloma.

Similar to bortezomib, but administered orally, MLN9708 is the first oral drug to go into clinical trial for myeloma. MLN9708 is boron-based making it a reversible inhibitor.

Current trials using the experimental drug aim to determine the dosage and efficacy in myeloma. Patients receiving the drug have already been heavily treated with commonly available agents and had high efficacy, with very low rates of neuropathy, when used in combination with other drugs.

en Español